RA
BBIO icon

Rise Advisors’s BridgeBio Pharma BBIO Stock Holding History

Rise Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-309
Closed -$16K – 237
2025
Q3 		$16K Hold
309
– – 0.01% 711
2025
Q2 		$13.3K Hold
309
– – 0.01% 816
2025
Q1 		$10.7K Buy
+309
New +$10.4K ﹤0.01% 922

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rise Advisors's BBIO Position: Q4 2025 in Review

Rise Advisors sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 309 shares — an estimated $16K sold.

Rise Advisors first reported a position in BBIO in Q1 2025 and held it in 3 quarters. The position peaked at $16K in Q3 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Rise Advisors reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 309 BridgeBio Pharma shares in Q4 2025, an estimated $16K.
  • Rise Advisors first reported a position in BridgeBio Pharma in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's BridgeBio Pharma position peaked at $16K in Q3 2025.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.